Fidelity Biosciences

Denali Therapeutics launches to study neurodegenerative disease treatments

Friday, May 15, 2015

Denali Therapeutics, a new California-based biotechnology company focused on developing effective therapies for neurodegenerative diseases, has launched with an initial investment commitment of $217 million. Denali is based on the collaboration of world-class scientists, industry experts and investors. Recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines for Alzheimer’s disease, Parkinson’s disease, ALS and other neurodegenerative diseases.

[Read More]

Fidelity Biosciences and Atlas Venture launch Unum Therapeutics

Wednesday, October 22, 2014

Fidelity Biosciences and Atlas Venture, with participation from SanofiGenzyme BioVentures, have launched Unum Therapeutics, a company developing cellular immunotherapy to treat cancer. Fidelity Biosciences invests venture capital in biopharmaceutical, medical technology, healthcare information technology and healthcare service companies, while Atlas Venture is an early-stage investor. All three are based in Cambridge, Mass.

[Read More]